Rodman & Renshaw Downgrades Valeant Pharmaceuticals (VRX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
S&P Affirms Rating on Valeant Pharma (VRX) Amid Weak Q3 Report, Cut Outlook
November 8, 2016 12:17 PM ESTS&P Global Ratings said its ratings and outlook on Valeant Pharmaceuticals International Inc. (NYSE: VRX) (B/Stable/--) are unchanged following the company's weak earnings report for the third quarter and lowered guidance for 2016. The company also indicated 2017 performance will likely be weaker than in 2016, because of the loss of exclusivity on certain neurology products. This contrasts with our prior expectation that 2017 would be materially stronger than 2016, given that 2016 has been a year of significant turbulence and transition for the company.
This represents a significant deterioration from our expectations and we are lowering our... More
Valeant Pharma (VRX) Misses Q3 EPS by 20c, Cuts FY16 Outlook
November 8, 2016 6:02 AM ESTValeant Pharma (NYSE: VRX) reported Q3 EPS of $1.55, $0.20 worse than the analyst estimate of $1.75. Revenue for the quarter came in at $2.48 billion versus the consensus estimate of $2.49 billion.
"This past quarter, we made further progress toward establishing the new Valeant," said Joseph C.... More
